The current stock price of AQST is 4.11 USD. In the past month the price decreased by -33.82%. In the past year, price increased by 38.85%.
ChartMill assigns a technical rating of 1 / 10 to AQST. When comparing the yearly performance of all stocks, AQST turns out to be only a medium performer in the overall market: it outperformed 49.46% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to AQST. AQST may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months AQST reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS decreased by -61.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.14% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
15 analysts have analysed AQST and the average price target is 9.29 USD. This implies a price increase of 126.11% is expected in the next year compared to the current price of 4.11.
For the next year, analysts expect an EPS growth of -26.94% and a revenue growth -23.71% for AQST
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 1T | ||
| JNJ | JOHNSON & JOHNSON | 20.6 | 578.208B | ||
| MRK | MERCK & CO. INC. | 22.54 | 302.633B | ||
| PFE | PFIZER INC | 9.06 | 154.765B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 126.196B | ||
| ZTS | ZOETIS INC | 18.55 | 56.153B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.774B | ||
| VTRS | VIATRIS INC | 5.76 | 16.793B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 222.91 | 9.202B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 142 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
AQUESTIVE THERAPEUTICS INC
30 Technology Dr
WARREN NEW JERSEY 07059 US
CEO: Keith J. Kendall
Employees: 142
Phone: 19089411900
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 142 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
The current stock price of AQST is 4.11 USD. The price increased by 7.03% in the last trading session.
AQST does not pay a dividend.
AQST has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
The Revenue of AQUESTIVE THERAPEUTICS INC (AQST) is expected to decline by -23.71% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
AQUESTIVE THERAPEUTICS INC (AQST) has a market capitalization of 501.42M USD. This makes AQST a Small Cap stock.
You can find the ownership structure of AQUESTIVE THERAPEUTICS INC (AQST) on the Ownership tab.